CA2989313A1 - Treatment of nut midline carcinoma - Google Patents

Treatment of nut midline carcinoma

Info

Publication number
CA2989313A1
CA2989313A1 CA2989313A CA2989313A CA2989313A1 CA 2989313 A1 CA2989313 A1 CA 2989313A1 CA 2989313 A CA2989313 A CA 2989313A CA 2989313 A CA2989313 A CA 2989313A CA 2989313 A1 CA2989313 A1 CA 2989313A1
Authority
CA
Canada
Prior art keywords
alkyl
alkylene
cycloalkyl
heterocycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2989313A
Other languages
English (en)
French (fr)
Inventor
Steven B. Landau
Michael H. Kagey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tensha Therapeutics Inc
Original Assignee
Tensha Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tensha Therapeutics Inc filed Critical Tensha Therapeutics Inc
Publication of CA2989313A1 publication Critical patent/CA2989313A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2989313A 2015-06-26 2016-06-24 Treatment of nut midline carcinoma Abandoned CA2989313A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185203P 2015-06-26 2015-06-26
US62/185,203 2015-06-26
PCT/US2016/039270 WO2016210275A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Publications (1)

Publication Number Publication Date
CA2989313A1 true CA2989313A1 (en) 2016-12-29

Family

ID=56409188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989313A Abandoned CA2989313A1 (en) 2015-06-26 2016-06-24 Treatment of nut midline carcinoma

Country Status (14)

Country Link
US (1) US20180193350A1 (enExample)
EP (1) EP3314005A1 (enExample)
JP (1) JP2018520124A (enExample)
KR (1) KR20180035785A (enExample)
CN (1) CN107787227A (enExample)
AR (1) AR105124A1 (enExample)
AU (1) AU2016283020A1 (enExample)
BR (1) BR112017028178A2 (enExample)
CA (1) CA2989313A1 (enExample)
HK (1) HK1252062A1 (enExample)
IL (1) IL256186A (enExample)
MA (1) MA42249A (enExample)
MX (1) MX2017016337A (enExample)
WO (1) WO2016210275A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
KR20160130778A (ko) 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP4629984A1 (en) * 2022-12-06 2025-10-15 BioVentures, LLC Development of potent dual hdac/brd4 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
SI2496582T1 (sl) 2009-11-05 2016-04-29 Glaxosmithkline Llc Corporation Service Company Benzodiazepinski inhibitor bromodomene
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
EP2496580B1 (en) 2009-11-05 2013-12-11 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX384074B (es) * 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
KR20160130778A (ko) 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료

Also Published As

Publication number Publication date
IL256186A (en) 2018-02-28
BR112017028178A2 (en) 2018-08-28
AR105124A1 (es) 2017-09-06
WO2016210275A1 (en) 2016-12-29
MX2017016337A (es) 2018-11-22
MA42249A (fr) 2018-05-02
AU2016283020A1 (en) 2018-01-04
US20180193350A1 (en) 2018-07-12
JP2018520124A (ja) 2018-07-26
EP3314005A1 (en) 2018-05-02
KR20180035785A (ko) 2018-04-06
CN107787227A (zh) 2018-03-09
HK1252062A1 (zh) 2019-05-10

Similar Documents

Publication Publication Date Title
US20180193350A1 (en) Treatment of nut midline carcinoma
US12357604B2 (en) Topical formulations of cannabinoids and use thereof in the treatment of pain
RU2566821C2 (ru) Модулятор nmda-рецептора со стабилизированной вторичной структурой и его применение
US20230129598A1 (en) Methods of treating estrogen receptor-associated diseases
JP2022512643A (ja) Ｅ３リガーゼの共有結合による標的化
RU2722179C2 (ru) Лечение состояний, ассоциированных с гиперинсулинемией
AU2018253937A1 (en) Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof
KR20120129954A (ko) ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP2022505645A (ja) 複素環キナーゼ阻害剤及びその使用
JP2015524446A (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
WO2008115443A1 (en) Kinase protein binding inhibitors
JP5344910B2 (ja) 薬剤耐性癌の処置方法
EP4313052A1 (en) Alk-5 inhibitors and uses thereof
JP2009537626A (ja) ９−ヒドロキシエリプチシン誘導体による悪性表現型の復帰変異
TW202333704A (zh) 用於治療腫瘤的藥物組合及其應用
US20200188410A1 (en) Cxcr7 inhibitors for the treatment of cancer
US20250170097A1 (en) Cathepsin inhibitors and use thereof in a method for detecting and treating resistance to immunotherapy
KR102571296B1 (ko) P-tau를 감소시키고 인지를 개선하는 알로스테릭 코르티코트로핀-방출 인자 수용체 1 (crfr1) 길항제
TW202026001A (zh) 用於癌症治療之ＴＧＦβ抑制劑及ＣＤＫ抑制劑之組合
TWI818948B (zh) 啉酮衍生物
WO2024097632A1 (en) Methods of reducing miro1 or phosphorylated alpha-synuclein
JP2024031105A (ja) 線維症治療又は予防薬
US10556889B1 (en) Salvinorin derivatives
Zeng et al. Development of Preladenant-Based Radiotracers for Imaging A2AR in Tumors
CA3166527A1 (en) Compositions and methods for treating neurodegenerative, neurodevelopmental, myodegenerative, and lysosomal storage disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220916